Merck's Best Seller Keytruda Racks Up Another Regulatory Win

Merck's vaunted checkpoint inhibitor Keytruda racked up another regulatory win. On Wednesday, the U.S. Food and Drug Administration greenlit the combination of Keytruda and Eisai's Lemvima as a first-line treatment for adult patients with advanced renal cell carcinoma (RCC).